BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Given Consensus Recommendation of “Moderate Buy” by Analysts

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) has been given an average recommendation of “Moderate Buy” by the six ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $24.25.

A number of equities analysts recently issued reports on BBOT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research note on Thursday, June 18th. HC Wainwright upped their price target on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Canaccord Genuity Group started coverage on shares of BridgeBio Oncology Therapeutics in a research note on Monday, May 11th. They issued a “buy” rating and a $23.00 price target on the stock. Oppenheimer started coverage on shares of BridgeBio Oncology Therapeutics in a research note on Monday, June 22nd. They issued an “outperform” rating and a $22.00 price target on the stock. Finally, Wall Street Zen cut shares of BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th.

BridgeBio Oncology Therapeutics Trading Up 3.5%

Shares of BBOT stock opened at $7.66 on Tuesday. BridgeBio Oncology Therapeutics has a 12 month low of $7.00 and a 12 month high of $14.87. The company has a market cap of $613.62 million, a PE ratio of -3.74 and a beta of 0.29. The firm’s fifty day simple moving average is $8.23.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last announced its earnings results on Tuesday, May 12th. The company reported ($526.11) EPS for the quarter. Equities research analysts expect that BridgeBio Oncology Therapeutics will post -2.33 earnings per share for the current year.

Hedge Funds Weigh In On BridgeBio Oncology Therapeutics

A number of hedge funds have recently bought and sold shares of BBOT. CIBC Private Wealth Group LLC bought a new position in BridgeBio Oncology Therapeutics during the 4th quarter valued at about $63,000. Persistent Asset Partners Ltd bought a new position in BridgeBio Oncology Therapeutics during the 4th quarter valued at about $107,000. Squarepoint Ops LLC bought a new position in BridgeBio Oncology Therapeutics during the 4th quarter valued at about $144,000. Quadrature Capital Ltd bought a new position in BridgeBio Oncology Therapeutics during the 4th quarter valued at about $162,000. Finally, BIT Capital GmbH bought a new position in BridgeBio Oncology Therapeutics during the 4th quarter valued at about $313,000. Institutional investors own 54.89% of the company’s stock.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.